Status of vaccine research and development for Shigella
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Shigella are gram-negative bacteria that cause severe diarrhea and dysentery. In 2013, Shigella infections caused an estimated 34,400 deaths in children less than five years old and, in 2010, an estimated 40,000 deaths in persons older than five years globally. New disease burden estimates from newly deployed molecular diagnostic assays with increased sensitivity suggest that Shigella-associated morbidity may be much greater than previous disease estimates from culture-based methods. Primary prevention of this disease should be based on universal provision of potable water and sanitation methods and improved personal and food hygiene. However, an efficacious and low-cost vaccine would complement and accelerate disease reduction while waiting for universal access to water, sanitation, and hygiene improvements. This review article provides a landscape of Shigella vaccine development efforts. No vaccine is yet available, but human and animal challenge-rechallenge trials with virulent Shigella as well as observational studies in Shigella-endemic areas have shown that the incidence of disease decreases following Shigella infection, pointing to biological feasibility of a vaccine. Immunity to Shigella appears to be strain-specific, so a vaccine that covers the most commonly detected strains (i.e., S. flexneri 2a, 3a, 6, and S. sonnei) or a vaccine using cross-species conserved antigens would likely be most effective. Vaccine development and testing may be accelerated by use of animal models, such as the guinea pig keratoconjunctivitis or murine pneumonia models. Because there is no correlate of protection, however, human studies will be necessary to evaluate vaccine efficacy prior to deployment. A diversity of Shigella vaccine constructs are under development, including live attenuated, formalin-killed whole-cell, glycoconjugate, subunit, and novel antigen vaccines (e.g., Type III secretion system and outer membrane proteins).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Kotloff, K. L., Nataro, J. P., Blackwelder, W. C., Nasrin, D., Farag, T. H., Panchalingam, S., Wu, Y., Sow, S. O., Sur, D., Breiman, R. F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60844-2 · Cited by 3,560
Norton, E. B., Lawson, L. B., Freytag, L. C., & Clements, J. D. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00538-10 · Cited by 221
Enhancing Oral Vaccine Potency by Targeting Intestinal M Cells
Azizi, A., Kumar, A., Diaz-Mitoma, F., & Mestecky, J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001147 · Cited by 180
Cited by
Khalil, I. A., Troeger, C., Blacker, B. F., Rao, P. C., Brown, A., Atherly, D. E., Brewer, T. G., Engmann, C. M., Houpt, E. R., Kang, G., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30475-4 · Cited by 710
Kotloff, K. L., Riddle, M. S., Platts-Mills, J. A., Pavlinac, P., & Zaidi, A. K. M. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33296-8 · Cited by 577
The role of vaccines in combatting antimicrobial resistance
Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00506-3 · Cited by 500
Rogawski, E. T., Liu, J., Platts-Mills, J. A., Kabir, F., Lertsethtakarn, P., Siguas, M., Khan, S. S., Praharaj, I., Murei, A., Nshama, R., et al. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30351-6 · Cited by 387
Cassotta, A., Goldstein, J. D., Durini, G., Jarrossay, D., Baggi Menozzi, F., Venditti, M., Russo, A., Falcone, M., Lanzavecchia, A., Gagliardi, M. C., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202048630 · Cited by 23
Metadata
- Authors
- Mani, S., Wierzba, T., & Walker, R. I.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 34
- Issue
- 26
- Pages
- 2887-2894
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2410338561
- Cited by
- 229
- References
- 7
- FWCI
- 20.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Status of vaccine research and development for Shigella. https://app.cochat.ai/papers/10.1016/j.vaccine.2016.02.075
- The paper
- Mani, S., Wierzba, T., & Walker, R. I. (2016). Status of vaccine research and development for Shigella. Vaccine. https://doi.org/10.1016/j.vaccine.2016.02.075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.